Drug-induced QT interval prolongation: regulatory perspectives and drug development.
作者： Rashmi Shah
DOI: 10.1080/17431380410032445
关键词: Pharmacogenetics 、 Drug development 、 QT interval 、 Heart disease 、 Prolongation 、 Pharmacology 、 Clinical trial 、 Mechanism (biology) 、 Medicine 、 Drug
摘要: Drug‐induced torsade de pointes is a modern, iatrogenic challenge. This potentially fatal tachyarrhythmia associated with many non‐antiarrhythmic (including non‐cardiovascular) drugs, leading to number of effective drugs being withdrawn from the market. Others have attracted severe prescribing restrictions while some new chemical entities experienced difficulties in gaining regulatory approval. Since QT interval prolongation, surrogate torsade, mechanism‐based concentration‐dependent pharmacological effect, it usually possible characterise drug for this toxicity during its development. The physicochemical and other properties QT‐prolonging modulate clinical risk pointes. Apart these properties, torsadogenic potential also influenced clinically by genetic non‐genetic factors. former include polymorphisms enzymes that metabolise or target. Major factor...
informahealthcare.com参考文章(12)
Hiroshi Furushima, Masaomi Chinushi, Takashi Washizuka, Yoshifusa Aizawa, Role of alpha1-blockade in congenital long QT syndrome: investigation by exercise stress test. Japanese Circulation Journal-english Edition. ,vol. 65, pp. 654- 658 ,(2001) , 10.1253/JCJ.65.654
Diane K. Wysowski, Janos Bacsanyi, Cisapride and fatal arrhythmia. The New England Journal of Medicine. ,vol. 335, pp. 290- 291 ,(1996) , 10.1056/NEJM199607253350416
Vicken R. Vorperian, Zhengfeng Zhou, Saeed Mohammad, Timothy J. Hoon, Christian Studenik, Craig T. January, Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. Journal of the American College of Cardiology. ,vol. 28, pp. 1556- 1561 ,(1996) , 10.1016/S0735-1097(96)00352-X
Raymond L. Woosley, Mechanism of the Cardiotoxic Actions of Terfenadine JAMA: The Journal of the American Medical Association. ,vol. 269, pp. 1532- 1536 ,(1993) , 10.1001/JAMA.1993.03500120070028
Mark T. Keating, Michael C. Sanguinetti, Molecular and cellular mechanisms of cardiac arrhythmias. Cell. ,vol. 104, pp. 569- 580 ,(2001) , 10.1016/S0092-8674(01)00243-4
Christopher Krasucki, Fran McFarlane, Electrocardiograms, high-dose antipsychotic treatment and College guidelines The Psychiatrist. ,vol. 20, pp. 326- 330 ,(1996) , 10.1192/PB.20.6.326
Walter Smalley, Deborah Shatin, Diane K. Wysowski, Jerry Gurwitz, Susan E. Andrade, Michael Goodman, K. Arnold Chan, Richard Platt, Stephanie D. Schech, Wayne A. Ray, Contraindicated Use of Cisapride JAMA. ,vol. 284, pp. 3036- 3039 ,(2000) , 10.1001/JAMA.284.23.3036
WS Redfern, L Carlsson, AS Davis, WG Lynch, IL MacKenzie, S Palethorpe, PKS Siegl, I Strang, AT Sullivan, R Wallis, AJ Camm, TG Hammond, Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs : Evidence for a provisional safety margin in drug development Cardiovascular Research. ,vol. 58, pp. 32- 45 ,(2003) , 10.1016/S0008-6363(02)00846-5
Ping Yang, Hideaki Kanki, Benoit Drolet, Tao Yang, Jian Wei, Prakash C. Viswanathan, Stefan H. Hohnloser, Wataru Shimizu, Peter J. Schwartz, Marshall Stanton, Katherine T. Murray, Kris Norris, Alfred L. George, Dan M. Roden, Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes Circulation. ,vol. 105, pp. 1943- 1948 ,(2002) , 10.1161/01.CIR.0000014448.19052.4C
Rashmi R. Shah, The significance of QT interval in drug development. British Journal of Clinical Pharmacology. ,vol. 54, pp. 188- 202 ,(2002) , 10.1046/J.1365-2125.2002.01627.X